Cardiology Headline News

Salt substitution may reduce the risk for all-cause and cardiovascular mortality, and it may also reduce the risk for major cardiovascular events, according to a systematic review and meta-analysis randomized controlled trials.

ATLANTA — In the DanGer-Shock trial, routine use of a microaxial flow pump, on top of standard care, led to a lower risk for death compared with standard care only for treatment of patients with STEMI and cardiogenic shock.

ATLANTA — Enalapril plus standard care was not superior to standard care alone for preventing cardiotoxicity in patients receiving treatment for breast cancer or lymphoma, according to new data from the PROACT trial.

ATLANTA — In a real-world population of patients with severe aortic stenosis at low or intermediate surgical risk, transcatheter aortic valve replacement was noninferior to surgery for death and stroke at 1 year, researchers reported.

ATLANTA — New results from the TACTiC trial show the promise of technology to help individuals appropriately determine if they qualify for statin therapy without a prescription.

ATLANTA — Adults with uncontrolled and treatment-resistant hypertension saw a modest reduction in 24-hour ambulatory BP with alcohol-mediated renal nerve denervation, although other mixed findings complicate the picture, researchers reported.

ATLANTA — A screening study presented at the American College of Cardiology Scientific Session showed that there is a high prevalence of unrecognized heart disease among former National Football League players.

The risk for mental health conditions and self-harm or suicide was higher among partners and adult offspring of stroke survivors vs. the general population and family of myocardial infarction survivors, according to a study in Denmark.

ATLANTA — In patients with ACS who underwent PCI, ticagrelor monotherapy after 1 month lowered bleeding risk by 55% compared with dual antiplatelet therapy for 12 months, according to the results of the ULTIMATE-DAPT trial.

ATLANTA — For patients with atherosclerotic CVD, an inclisiran-first strategy was associated with greater lowering of LDL compared with the usual care, researchers reported at the American College of Cardiology Scientific Session.